Manufacturing / Pharmaceutical Preparations
JOHNSON & JOHNSON
JNJ
$228.45
+$0.06 (+0.03%)
550 B
Market Cap (Mega Cap)
76%
IV Rank
25.7%
Implied Volatility
Jul 14
Next Earnings
Insider Trades
1 buys
22 sells
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | Wengel Kathryn E | Exercise | 10,000 | $0 | |
| Jun 11, 2026 | Wengel Kathryn E | Sell | 10,000 | $2,411,500 | |
| Jun 11, 2026 | Wengel Kathryn E | Exercise | 10,000 | $1,156,700 | |
| Jun 11, 2026 | Wengel Kathryn E | Other | 10,000 | $0 | |
| Jun 11, 2026 | Wengel Kathryn E | Other | 10,000 | $2,411,500 | |
| Jun 11, 2026 | Wengel Kathryn E | Other | 10,000 | $1,156,700 | |
| Jun 09, 2026 | Woods Eugene A. | Grant | 161 | $37,479 | |
| Jun 09, 2026 | Pinto Daniel E | Grant | 134 | $31,194 | |
| Jun 09, 2026 | HEWSON MARILLYN A | Grant | 215 | $50,050 | |
| Jun 09, 2026 | Woods Eugene A. | Other | 161 | $37,479 |
Politician Trades in JNJ
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| Mar 19, 2026 | Rich McCormick | R | Sale | $1K-$15K |
| Mar 10, 2026 | Lloyd Alton Doggett | D | Purchase | $1K-$15K |
| Mar 06, 2026 | Ro Khanna | D | Sale | $1K-$15K |
| Feb 05, 2026 | Ro Khanna | D | Purchase | $1K-$15K |
| Jan 23, 2026 | Thomas Kean | R | Sale | $15K-$50K |
| Dec 18, 2025 | Julie Johnson | D | Sale | $1K-$15K |
| Dec 09, 2025 | Lloyd Alton Doggett | D | Purchase | $1K-$15K |
| Nov 20, 2025 | Thomas Kean | R | Sale | $15K-$50K |
| Nov 13, 2025 | Julie Johnson | D | Sale | $1K-$15K |
| Nov 07, 2025 | Ro Khanna | D | Purchase | $15K-$50K |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Mar 31, 2026 | Q1 2026 | $2.69 | $2.70 | +0.3% | Beat |
| Dec 31, 2025 | Q4 2025 | $2.46 | $2.46 | -0.1% | Miss |
| Sep 30, 2025 | Q3 2025 | $2.78 | $2.80 | +0.5% | Beat |
| Jun 30, 2025 | Q2 2025 | $2.71 | $2.77 | +2.3% | Beat |
Track JNJ with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for JNJ and your entire portfolio.